DVAX (Dynavax Pharma) Market Value to Book Value Ratio

Official company branding of Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX) generates revenue through the sale of hepatitis B vaccines and the supply of adjuvants, which diversifies its income streams. Stable management has ensured a resilient balance sheet and a cash position of 3.38. The asset's price trajectory is illustrated in the chart below. Management has successfully transitioned the business into an active sales phase, focusing on expanding target markets and identifying new applications for its technological platform.

DVAX Dynavax Technologies Corp: Market Value to Book Value in the range 07/04/2022 - 02/21/2026

Financial and market metric breakdowns for dynavax.com (DVAX)

- price and consensus price forecast:
Stock Quotes Dynavax Pharma|DVAX - Broker Consensus Forecast
- market capitalization data:
Market Value Dynavax Corp|DVAX - Full Business Value
- book capitalization data:
Book Value per Share Dynavax|DVAX - Accounting Value of Company|Market Capitalization to Book Value Ratio dynavax.com|DVAX - Company Total Assets
- debt and liquidity data:
Debt to Equity Dynavax Technologies|DVAX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Dynavax|DVAX - Company Total Debt|Debts to Book Capitalization Dynavax Corp|DVAX - Company Long-Term Debts|Company Current Liabilities Dynavax
Initial company analysis:Dynavax Technologies Corp - DVAX
Original product of Dynavax

This indicator measures the market value premium over net assets, reflecting investor expectations regarding future returns on capital. By analyzing the market cap to book capitalization multiple, one can see how proprietary immune component protection and FDA barriers transform the tangible assets of Dynavax Technologies (DVAX) into a high market valuation, determining the growth potential or the risk of a stock correction.

Main competitors

Market Cap to Net Assets Ratio Arrowhead Pharmaceuticals|MIRM (mirumpharma.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Arbutus Biopharma Corporation ABUS|Market Capitalization to Net Assets Inventiva SA|Gyre Corp (GYRE) - Market Capitalization to Book Value Ratio|Market Value to Book Value Assembly Corp (ASMB)|Market Capitalization to Book Value Ratio GALT (Galectin Therapeutics Inc.)|Genfit SA - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio DURECT Corp. (DRRX)|ALGS: Market Value to Book Value|BIVI (biovieinc.com) - Market Value to Book Value Ratio|Galmed Pharmaceuticals Ltd. (GLMD) - Market Cap to Net Assets Ratio|NDRA (ENDRA Life Sciences) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Hepion Pharma (HEPA)